StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Zerbaxa (ceftolozane and tazobactam) by Quarter

Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Zerbaxa (ceftolozane and tazobactam): 4.0% in Q2 2026, down 17.0 pts from a year earlier.

Latest, Q2 2026
4.0%
Period ended Jun 30, 2026
Change on a year earlier
-17.0 pts
21.0% in Q2 2025
History
21 quarters
Since Q1 2020
Sources
21
Documents cited below

Where the Q2 2026 figure comes from

“|| Zerbaxa | 77 | 74 | 4 | 44 | 45 | -3 | 34 | 29 | 14”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20264.0%-17.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202524.0%+10.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202525.0%+3.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202521.0%+7.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 202524.0%+11.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202414.0%-11.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202422.0%-1.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202414.0%-3.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202413.0%-53.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202325.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202323.0%–Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202317.0%–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 202366.0%–Form 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q4 2021Dec 31, 2021-47.0%-5.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-105.0%-127.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2021Jun 30, 2021-104.0%-123.0 ptsForm 8-K (tm2123400d1_ex99-1.htm, filed 2021-07-29) ↗

Cite this data

StockData. (2026). Merck Zerbaxa (ceftolozane and tazobactam) (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zerbaxa-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.